New Therapeutics to Treat Castrate-Resistant Prostate Cancer
The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patient...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2013/379641 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563997982851072 |
|---|---|
| author | Ömer Acar Tarık Esen Nathan A. Lack |
| author_facet | Ömer Acar Tarık Esen Nathan A. Lack |
| author_sort | Ömer Acar |
| collection | DOAJ |
| description | The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage prostate cancer. In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials. |
| format | Article |
| id | doaj-art-89e1bc989e6049a2b5c09a8e07ca45f3 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-89e1bc989e6049a2b5c09a8e07ca45f32025-02-03T01:12:01ZengWileyThe Scientific World Journal1537-744X2013-01-01201310.1155/2013/379641379641New Therapeutics to Treat Castrate-Resistant Prostate CancerÖmer Acar0Tarık Esen1Nathan A. Lack2VKF American Hospital, Guzelbahce sokak, Nisantasi, Istanbul 34365, TurkeyVKF American Hospital, Guzelbahce sokak, Nisantasi, Istanbul 34365, TurkeyVKF American Hospital, Guzelbahce sokak, Nisantasi, Istanbul 34365, TurkeyThe effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage prostate cancer. In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials.http://dx.doi.org/10.1155/2013/379641 |
| spellingShingle | Ömer Acar Tarık Esen Nathan A. Lack New Therapeutics to Treat Castrate-Resistant Prostate Cancer The Scientific World Journal |
| title | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
| title_full | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
| title_fullStr | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
| title_full_unstemmed | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
| title_short | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
| title_sort | new therapeutics to treat castrate resistant prostate cancer |
| url | http://dx.doi.org/10.1155/2013/379641 |
| work_keys_str_mv | AT omeracar newtherapeuticstotreatcastrateresistantprostatecancer AT tarıkesen newtherapeuticstotreatcastrateresistantprostatecancer AT nathanalack newtherapeuticstotreatcastrateresistantprostatecancer |